ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Natural products proposed for the management of Huntington's disease (HD): a comprehensive review.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From nutrition to therapeutics: the diverse inflammopharmacological and biomedical roles of astaxanthin.Inflammopharmacology · 2026Review
- An integrative neuropharmacological review of Huntington's disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD), a neurodegenerative disease, typically begins in the prime of adulthood, followed by a gradual onset of specific mental abnormalities and cognitive and physical impairment. To the best of our knowledge, no medication exists to totally stop the progression of HD. Among numerous therapy techniques, extensive literature reviews have confirmed the medicinal importance of natural products in HD experimental models. This review provides a literature survey of natural compounds and medicinal plants used as neuroprotective agents against HD. Relevant studies were found in a variety of scientific databases, including PubMed, ScienceDirect, Scopus, and Google Scholar. Overall, natural products provided various levels of neuroprotection in preclinical HD investigations through antioxidant and anti-inflammatory activities, mitochondrial function maintenance, apoptosis suppression, and autophagy induction. Plants such as Bacopa monnieri, Ginkgo biloba, Panax ginseng, and Withaniasomnifera were identified as the most promising anti-HD possibilities, with several of them known as CNS-active medicines. Curcumin, epigallocatechin-gallate, ginsenosides, kaempferol, naringin, and resveratrol were identified as anti-HD compounds, some of which are well recognized neuroprotectants. Further study is required to assess the therapeutic efficacy of new herbal extracts in HD animals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.